An Empirical Evaluation of the Diagnostic Criteria for Premenstrual Dysphoric Disorder: Problems with Sex Specificity and Validity

Callaghan, Glenn M.; Chacon, Cynthia; Coles, Cameron; Botts, Julie; Laraway, Sean

doi:10.1080/02703140802402396

Cited by 4 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most frequently used measure of prospective symptom reporting is the Daily Record of Severity of Problems (DRSP; Endicott, Nee, & Harrison, 2006). A significant advantage of this method is that it tends to have increased accuracy, given that research has demonstrated poor specificity for retrospective reports of premenstrual symptoms (e.g., recalling typical premenstrual symptoms; Callaghan et al, 2009;O'Brien et al, 2011). For example, researchers found that retrospective recall of premenstrual symptoms correlates with prospective ratings in approximately 50% of cases, and only 20-50% of women who report meeting PMDD criteria continue to meet criteria after prospective rating for two cycles (Davis & Yonkers, 1997).…”

Section: Please Scroll Down For Articlementioning

confidence: 99%

Does a Disconnect Occur Between Research and Practice for Premenstrual Dysphoric Disorder (PMDD) Diagnostic Procedures?

2014

View full text Add to dashboard Cite

Diagnostic assessment recommendations for premenstrual dysphoric disorder (PMDD) include the use of daily symptom monitoring for two consecutive menstrual cycles; however, it is unclear whether medical providers use this established procedure in practice. This study explored typical diagnostic procedures for PMDD among a sample of physicians (N = 87) who were recruited by mail and completed questions about current practices. Results indicated that only 11.5% of physicians in this sample reported routinely using 60-day symptom monitoring, and only 18.4% of physicians reported regular use of any type of daily symptom monitoring. No differences were observed in these procedures based on frequency of contact with patients with PMDD or physician type (obstetrics and gynecology [OB/GYN] or family medicine). Overall, these results indicated that it is important to establish standard assessment methods for PMDD that have clinical utility for physicians, as well as increase awareness of research-based practice in diagnosing PMDD.

show abstract

Section: Please Scroll Down For Articlementioning

confidence: 99%

Does a Disconnect Occur Between Research and Practice for Premenstrual Dysphoric Disorder (PMDD) Diagnostic Procedures?

2014

View full text Add to dashboard Cite

show abstract

“…Cosgrove and Caplan, 2004) and continues with the DSM-5, as PMDD will be incorporated into the text as a mood disorder for the first time. Decades of research have failed to provide clear and consistent empirical support for PMDD as a separate disease entity, and serious methodological problems have been identified in those studies claiming that the etiology is hormonal (Callaghan et al, 2009; Di Giulio and Riessing, 2006; Gallant et al, 1992). The reliability of the diagnosis also has been a source of major criticism since there are no standardized assessments for diagnosis (Caplan, 1995; Wittchen, 2010).…”

Section: Premenstrual Dysphoric Disorder and The Hegemony Of A Biopsymentioning

confidence: 99%

Industry’s colonization of psychiatry: Ethical and practical implications of financial conflicts of interest in the DSM-5

Cosgrove

Wheeler

2013

Feminism & Psychology

View full text Add to dashboard Cite

The revision of the Diagnostic and Statistical Manual of Mental Disorders (DSM), scheduled for publication in May 2013 by the American Psychiatric Association (APA), has created a firestorm of controversy because of questions about undue industry influence. Specifically, concerns have been raised about financial conflicts of interest between DSM-5 panel members and the pharmaceutical industry. The authors argue that current approaches to the management of these relationships, particularly transparency of them, are insufficient solutions to the problem of industry’s capture of organized psychiatry. The conceptual framework of institutional corruption is used to understand psychiatry’s dependence on the pharmaceutical industry and to identify the epistemic assumptions that ground the DSM’s biopsychiatric discourse. APA’s rationale for including premenstrual dysphoric disorder in the DSM-5 as a Mood Disorder is reviewed and discussed.

show abstract

“…These disorders were selected because of the questions raised regarding their validity [12,13,14,15], concerns that these diagnoses lack specificity and will result in unnecessary diagnostic inflation [16], and documented problems with reliability [14,17]. …”

Section: Methodsmentioning

confidence: 99%

Tripartite Conflicts of Interest and High Stakes Patent Extensions in the DSM-5

Cosgrove

Krimsky

Wheeler

et al. 2014

Psychother Psychosom

View full text Add to dashboard Cite

Background: The revision process for and recent publication of the DSM-5 initiated debates about the widening of diagnostic boundaries. The pharmaceutical industry had a major financial stake in the outcome of these debates. This study examines the three-part relationship among DSM panel members, principal investigators (PIs) of clinical trials for new DSM-5 diagnoses, and drug companies. Methods: Financial conflicts of interest (FCOI) of DSM panel members responsible for some new diagnoses in the DSM-5 and PIs of clinical trials for related drug treatments were identified. Trials were found by searching ClinicalTrials.gov. Patent and revenue information about these drugs was found using the US Food and Drug Administration's Orange Book and manufacturer Annual Reports. Results: Thirteen trials met inclusion criteria (testing drugs for some new DSM disorders). Sixty-one percent of the DSM Task Force members and 27% of Work Group members reported FCOI to the trial drug manufacturers. In 5 of the 13 trials (38%), PIs reported ties other than research funding to the drug manufacturer. In 3 of the trials (23%), a PI had financial ties to the drug manufacturer and was also a DSM panel member who had decision-making authority over the revision process. Conclusions: These findings suggest that increased transparency (e.g., registration on ClinicalTrials.gov) and mandatory disclosure policies (e.g., the American Psychiatric Association's disclosure policy for DSM-5 panel members) alone may not be robust enough strategies to prevent the appearance of bias in both the DSM revision process as well as clinical decisions about appropriate interventions for DSM disorders.

show abstract

An Empirical Evaluation of the Diagnostic Criteria for Premenstrual Dysphoric Disorder: Problems with Sex Specificity and Validity

Cited by 4 publications

References 30 publications

Does a Disconnect Occur Between Research and Practice for Premenstrual Dysphoric Disorder (PMDD) Diagnostic Procedures?

Does a Disconnect Occur Between Research and Practice for Premenstrual Dysphoric Disorder (PMDD) Diagnostic Procedures?

Industry’s colonization of psychiatry: Ethical and practical implications of financial conflicts of interest in the DSM-5

Tripartite Conflicts of Interest and High Stakes Patent Extensions in the DSM-5

Contact Info

Product

Resources

About